News & Resources
Discussing research multi-biomarker advances in Alzheimer’s Disease at ADPD 2025
This week we will be at the ADPD 2025 International Conference talking about some of our latest biomarker research. Specifically, we are presenting an AI-based approach to differentiate different types of dementia from magnetic resonance imaging (MRI).
Huntington's Disease: Your Imaging Analysis & Operations Solutions Partner
Transforming clinical research in Huntington’s diseaseEstablished for over 20 years, IXICO is the leading provider of neuroimaging services for Huntington’s disease (HD) clinical trials. Our mission is to advance investigational therapies through innovative imaging solutions that comply with global regulatory standards.
Your Imaging Analysis & Operations Experts in Alzheimer’s Disease Clinical Research
IXICO’s Alzheimer’s Disease Footprint at a GlancePioneering Precision in AD Imaging IXICO excels in AD imaging with advanced imaging biomarkers to quantify markers such as amyloid plaques, tau tangles, and brain atrophy. Our AI-driven IXIQ. Ai platform enhances the accuracy and efficiency of brain imagine measurements.
Executing a Multi-Arm Phase 1 Alzheimer’s Disease Global Clinical Trial with Clinilabs and IXICO
In the realm of Central Nervous System (CNS) clinical trials, the expertise in science and technology is constantly being pushed to new boundaries.
Comparison of two natural history studies as part of the HD-IH consortium: a use case for historical external control group matching in clinical trials
External control groups can support regulatory decision-making in clinical trials, especially rare diseases. In Huntington’s disease (HD) there is a wealth of historical data, but matching historical data to clinical trials is challenging.
International Women's Day 2025
International Women's Day (IWD) has been around for over a hundred years, as have many of the issues still impacting women's advancement. Since 1911, IWD belongs to all who care about women's equality, celebrating women's achievement, raising awareness about discrimination and taking action to forge gender parity.
Contract Wins in Alzheimer’s and Huntington’s Disease
27 February 2025 - London, UK. IXICO plc (AIM: IXI, “IXICO” or “the Company”) a global leader in neuroscience imaging, using its AI-driven platform to help advance therapy research in neurological disorders, today announces that it has signed a new commercial contract for a global Alzheimer’s Disease (AD) imaging analysis with a leading biotechnology company, and secured an additional project in Huntington’s Disease (HD) with an existing partner.
1-8 of 154 results